Elvitegravir (JTK-303; GS-9137) is an orally active human immunodeficiency virus type 1 (HIV-1) integrase inhibitor that prevents HIV-1 replication (EC50 = 0.9 nM using HTLV-I transformed T4-cell line MT-4) by blocking viral DNA to host DNA strand transfer (IC50 = 7.2 nM by cell-free assays).
Orally active human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor.
Integrase (IN), an essential enzyme of human immunodeficiency virus (HIV), is an attractive antiretroviral drug target. The antiviral activity and resistance profile in vitro of a novel IN inhibitor, elvitegravir (EVG) (also known as JTK-303/GS-9137), currently being developed for the
Antimicrobial agents and chemotherapy, 52(6), 2069-2078 (2008-04-02)
To gain further insight into the understanding of the antiviral resistance patterns and mechanisms of the integrase strand transfer inhibitor L-870,810, the prototypical naphthyridine analogue, we passaged the human immunodeficiency virus type 1 strain HIV-1(III(B)) in cell culture in the
Journal of medicinal chemistry, 49(5), 1506-1508 (2006-03-03)
The viral enzyme integrase is essential for the replication of human immunodeficiency virus type 1 (HIV-1) and represents a remaining target for antiretroviral drugs. Here, we describe the modification of a quinolone antibiotic to produce the novel integrase inhibitor JTK-303
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.